bigger Created with Sketch.

News & Events

News & Events

For media inquiries, please email cmayfield@homologymedicines.com

SIGN UP FOR NEWS ALERTS

News
& Events

Current News & Events | Archived News & Events
06/29/2022
Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU ​
06/13/2022
Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU​
05/18/2022
Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression​
05/16/2022
Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights​
05/02/2022
Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting​
04/21/2022
Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President​
03/23/2022
Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights ​
03/10/2022
Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica​
03/03/2022
Homology Medicines to Participate in Upcoming Investor Conferences​
02/18/2022
Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU​
02/10/2022
Homology Medicines Announces Presentations on HMI-203 Investigational Gene Therapy for Hunter Syndrome and Broad Applicability of AAVHSC Platform for Lysosomal Storage Disorders at the 18th Annual WORLDSymposium™ Meeting​
01/27/2022
Oxford Biomedica broadens leading viral vector offerings by incorporating Homology Medicines’ established AAV capabilities into a newly formed AAV Manufacturing and Innovation Business in the U.S. with Homology Medicines as 20% owner​
11/15/2021
Homology Medicines Reports Third Quarter 2021 Financial Results and Recent Highlights​
11/03/2021
Homology Medicines to Participate in Upcoming Investor Conferences​
10/21/2021
Homology Medicines Announces Presentations Across Gene Therapy and Gene Editing Programs, including GTx-mAb, at European Society of Gene & Cell Therapy Meeting ​
10/20/2021
Homology Medicines Announces Presentation of Data Supporting Clinical Programs in MPS II and PKU, including Nonclinical and Patient-Focused Research, at American Society of Human Genetics Meeting​
10/18/2021
Homology Medicines Initiates Clinical Trial for HMI-203, a One-Time Investigational Gene Therapy Candidate for Adults with MPS II (Hunter Syndrome) ​
10/12/2021
Homology Medicines Announces World’s First Gene Editing Clinical Trial for PKU​
08/12/2021
Homology Medicines Reports Second Quarter 2021 Financial Results and Recent Highlights​
08/05/2021
Homology Medicines Appoints Gene Therapy Pioneer Beverly Davidson, Ph.D., as Chair of Scientific Advisory Board ​
08/04/2021
Homology Medicines to Participate in Upcoming Investor Conferences​